Skip to main content
Evidence Snapshot

cAMP-dependent protein kinase catalytic subunit beta

CHEMBL2918 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2918
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats cAMP-dependent protein kinase catalytic subunit beta as ChEMBL target CHEMBL2918, mapped to UniProt P22694. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
cAMP-dependent protein kinase catalytic subunit beta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2918
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P22694
cAMP-dependent protein kinase catalytic subunit beta
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why cAMP-dependent protein kinase catalytic subunit beta matters

As of 2026-09-13

cAMP-dependent protein kinase catalytic subunit beta is reviewed as cAMP-dependent protein kinase catalytic subunit beta (UniProt P22694); the current evidence base includes 3 approved drugs, 518 compounds, and 147 assays, with lead potency reaching pChEMBL 10.9.

Protein context
cAMP-dependent protein kinase catalytic subunit beta

cAMP-dependent protein kinase catalytic subunit beta Sequence length is 351 aa.

Review this target as cAMP-dependent protein kinase catalytic subunit beta, mapped to UniProt P22694. Sequence length is 351 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P22694 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 3 approved drugs, 518 compounds, and 147 assays for this target. The dominant activity type is KD. CHEMBL5190946 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL5190946 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine
3 approved pChEMBL 10.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why cAMP-dependent protein kinase catalytic subunit beta matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P22694, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

518
Total Compounds
147
Total Assays
3
Approved Drugs
IC50: 24.0, KD: 366.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5190946
 10.9 Kd —
No preferred name
CHEMBL388978
 9.2 IC50 —
No preferred name
CHEMBL5653589
 8.5 Kd —
No preferred name
CHEMBL494089
 7.9 Kd —
No preferred name
CHEMBL3544960
 7.8 Kd —

Approved Drugs

Structure Compound First Approval
CAPIVASERTIB
CHEMBL2325741
 2023
MIDOSTAURIN
CHEMBL608533
 2017
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2918